Please login to the form below

Not currently logged in
Email:
Password:

Amgen and Takeda lung drug fails trial

Amgen and Takeda have revealed that its lung cancer drug motesanib has failed to meet its endpoint in a phase III trial
Amgen and Takeda have revealed that its lung cancer drug motesanib has failed to meet its endpoint in a phase III trial. 

The drug failed to demonstrate an improvement in overall survival rate when combined with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.

In this trial, as in earlier trials of motesanib, the patients who received the drug were also more likely to experience serious adverse events more frequently than those who were given a placebo. Among the adverse events reported were hypertension and bleeding disorders.

Roger M Perlmutter, executive vice president of research and development at Amgen, said: "We are disappointed with the results from this trial, but look forward to further analysis of the data which may ultimately help inform future research in this area."

No decision has been made about continuing development.

31st March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Mapping content strategies to pharma lifecycle management
In these tough economic times, we should be ramping up our pharma lifecycle management (LCM) strategies. These are well-established strategies for managing and extending the commercial value of products. So...
Back from the future – innovation for pharma
After 5 days of seeing amazing innovations, having discussions about the future of medicine and the practicalities of living on Mars. Plus listening to inspiring speakers from fighter plane-flying physicians...
Cost containment and the German market
The healthcare system’s budget limitations will face further pressure from challenges such as personalised medicine...

Infographics